Discrete β-adrenergic mechanisms regulate early and late erythropoiesis in erythropoietin-resistant anemia

Surgery. 2017 Oct;162(4):901-916. doi: 10.1016/j.surg.2017.06.001. Epub 2017 Jul 14.

Abstract

Background: Anemia of critical illness is resistant to exogenous erythropoietin. Packed red blood cells transfusions is the only treatment option, and despite related cost and morbidity, there is a need for alternate strategies. Erythrocyte development can be divided into erythropoietin-dependent and erythropoietin-independent stages. We have shown previously that erythropoietin-dependent development is intact in burn patients and the erythropoietin-independent early commitment stage, which is regulated by β1/β2-adrenergic mechanisms, is compromised. Utilizing the scald burn injury model, we studied erythropoietin-independent late maturation stages and the effect of β1/β2, β-2, or β-3 blockade in burn mediated erythropoietin-resistant anemia.

Methods: Burn mice were randomized to receive daily injections of propranolol (nonselective β1/β2 antagonist), nadolol (long-acting β1/β2 antagonist), butoxamine (selective β2 antagonist), or SR59230A (selective β3 antagonist) for 6 days after burn. Total bone marrow cells were characterized as nonerythroid cells, early and late erythroblasts, nucleated orthochromatic erythroblasts and enucleated reticulocyte subsets using CD71, Ter119, and Syto-16 by flow cytometry. Multipotential progenitors were probed for MafB expressing cells.

Results: Although propranolol improved early and late erythroblasts, only butoxamine and selective β3-antagonist administrations were positively reflected in the peripheral blood hemoglobin and red blood cells count. While burn impeded early commitment and late maturation stages, β1/β2 antagonism increased the early erythroblasts through commitment stages via β2 specific MafB regulation. β3 antagonism was more effective in improving overall red blood cells through late maturation stages.

Conclusion: The study unfolds novel β2 and β3 adrenergic mechanisms orchestrating erythropoietin resistant anemia after burn, which impedes both the early commitment stage and the late maturation stages, respectively.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenergic Antagonists / pharmacology
  • Anemia / etiology*
  • Animals
  • Burns / complications*
  • Butoxamine / pharmacology
  • Disease Models, Animal
  • Erythropoiesis*
  • Male
  • Mice
  • Nadolol / pharmacology
  • Propanolamines / pharmacology
  • Propranolol / pharmacology
  • Receptors, Adrenergic, beta / drug effects
  • Receptors, Adrenergic, beta / physiology*

Substances

  • 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate
  • Adrenergic Antagonists
  • Propanolamines
  • Receptors, Adrenergic, beta
  • Butoxamine
  • Nadolol
  • Propranolol